Profusa Adds Leading Greek Vascular Surgeon to Customer Base
Rhea-AI Summary
Profusa (Nasdaq: PFSA) announced on January 8, 2026 that Dr. Theodosios Bisdas, Head of Clinic of Vascular Surgery at Athens Medical Center, will adopt the Lumee™ Oxygen tissue monitoring platform in his clinical practice in Greece and in clinical studies for home monitoring.
The agreement covers clinical integration for inpatient and outpatient care and continued evaluations of additional vascular applications. Dr. Bisdas has led major multicenter vascular research, published over 100 scientific articles, and founded Vascupedia, a platform with over 10,000 users in 124 countries. Profusa described the collaboration as an expansion of its vascular surgeon network at the Athens Medical Center.
Positive
- None.
Negative
- None.
News Market Reaction – PFSA
On the day this news was published, PFSA gained 0.10%, reflecting a mild positive market reaction. Argus tracked a peak move of +10.8% during that session. Argus tracked a trough of -2.2% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $9K to the company's valuation, bringing the market cap to $9M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
PFSA was down 3.07% while peers were mixed: AIMD up 1.7%, ALUR down 11.58%, others flat. No consistent sector direction indicated.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 31 | Commercial expansion | Positive | -14.0% | French Lumee distribution deal and EU commercialization plans disclosed. |
| Dec 30 | Debt restructuring | Positive | +78.3% | Restructured senior secured convertible notes to ease dilution and repayments. |
| Dec 15 | Clinical results | Positive | -19.9% | US Lumee study met primary endpoints in PAD patients over 12 months. |
| Dec 11 | Conference presentation | Positive | +0.6% | Acceptance of US pilot study abstract for LINC 2026 presentation. |
| Nov 24 | Conference acceptance | Positive | +8.4% | Late Breaking Clinical Trial Update slot at Paris Vascular Insights 2025. |
Recent news has been mostly positive (clinical and commercial), with mixed price reactions: three aligned upside moves and two sharp selloffs on good news.
Over the last few months, PFSA reported several milestones around its Lumee platform. On Nov 24, 2025 and Dec 11, 2025, it highlighted U.S. clinical trial presentations at Paris Vascular Insights and LINC 2026, followed by a Dec 15, 2025 update that the U.S. study met primary endpoints but saw a -19.87% reaction. A Dec 30, 2025 note restructuring announcement drove a 78.33% gain. On Dec 31, 2025, a French distribution deal still led to a -13.96% move. Today’s collaboration extends this commercialization and KOL-building trajectory.
Market Pulse Summary
This announcement adds a high-profile vascular surgeon and clinic in Greece to PFSA’s Lumee Oxygen user base, reinforcing a strategy of key opinion leader engagement and broader clinical use. It follows recent positive U.S. trial results and European commercialization plans. Investors may track how such collaborations translate into procedure volume and real-world data, while also considering the company’s disclosed financing, governance, and operational risks highlighted in recent SEC filings.
Key Terms
endovascular medical
vascular prostheses medical
multicenter study medical
ischemia medical
AI-generated analysis. Not financial advice.
Dr. Theodosios Bisdas is a renowned vascular surgeon and Head of Clinic of Vascular Surgery at the Athens Medical Center
BERKELEY, Calif, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual’s biochemistry, announces a collaboration with Theodosios Bisdas, M.D., Ph.D., FACS, Head of Clinic of Vascular Surgery, Athens Medical Center, Greece, and previously Associate Professor for Vascular Surgery, Universitätsklinikum Münster, Germany. Dr. Bisdas has extensive experience in innovative endovascular techniques and is a member of the advisory boards of several medical technology companies for new vascular prostheses. Under the agreement, Dr. Bisdas will adopt Lumee™ Oxygen tissue monitoring in his practice in Greece and in clinical studies that advance application of Lumee for home monitoring.
“Having used the Lumee Oxygen tissue monitoring in clinical trials, I look forward to integrating the technology in our practice at the Athens Medical Center. In addition, we will continue clinical evaluations of the platform for additional vascular applications where there is an unmet need. Based on my experience, the Lumee Oxygen tissue monitoring provides valuable treatment guidance and patient monitoring in both the inpatient and outpatient settings,” commented Dr. Bisdas.
Dr. Bisdas has extensive experience in endovascular interventions, and has led major research projects, including as principal investigator responsible for the largest open multicenter study (CRITISCH Registry) in the history of the German Society for Vascular Surgery for the treatment of critical ischemia of the lower extremities and diabetic foot. In addition to his clinical work, he is involved in medical teaching, advises medical technology companies, and is committed to humanitarian projects. Dr. Bisdas has published over 100 scientific articles. He is a member of the scientific committee of eleven international congresses, a reviewer for several prestigious journals, and a member of the editorial boards of the Journal of Endovascular Therapy, Vascular Surgery and Innovative Surgical Science. Further, Dr. Bisdas is a member of the American Society for Vascular Surgery, co-founder of the first Summer Academy for Vascular and Endovascular Surgery of the German Society for Vascular Surgery and Vascular Medicine (DGG e.V.), and founder of the internationally renowned platform Vascupedia with over 10,000 users in 124 countries.
"We welcome Dr. Bisdas to our roster of vascular surgeons as we continue to expand our network to now add the Vascular Surgery Clinic at the Athens Medical Center, Greece,” said Ben Hwang, Ph.D., Profusa’s Chairman and CEO. “We look forward to our collaboration with Dr. Bisdas as he integrates our Lumee Oxygen tissue monitoring to his practice as well as identifying opportunities for future clinical partnerships as we evaluate additional vascular applications of our platform technology.”
About Profusa
Based in Berkeley, Calif., Profusa is a commercial stage digital health company led by visionary scientific founders, an experienced management team and a world-class board of directors in the development of a new generation of tissue-integrated sensors to detect and continuously transmit actionable, medical-grade data for personal and medical use. With its long-lasting, injectable and affordable biosensors and its intelligent data platform, Profusa aims to provide people with a personalized biochemical signature rooted in data that clinicians can trust and rely on.
“LUMEE”, “PROFUSA” and the PROFUSA logo are registered trademarks of Profusa Inc. in the United States, Canada, European Union, China, Japan, South Korea and Australia.
For more information, visit https://profusa.com.
Special Note Regarding Forward-Looking Statements
Certain statements in this press release (this “Press Release”) may be considered “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or future financial or operating performance of Profusa. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “propose,” “seek,” “should,” “strive,” “will,” or “would” or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which may be beyond the control of Profusa and could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Profusa and its management are inherently uncertain. Profusa cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. There are risks and uncertainties described in the definitive proxy/final prospectus relating to the business combination, which has been filed with the SEC, and in other documents filed by Profusa from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Profusa cannot assure you that the forward-looking statements in this communication will prove to be accurate.
Contacts
Investor and Media Contacts
email: info@coreir.com
phone: 1 (212) 655-0924
FAQ
What did Profusa (PFSA) announce on January 8, 2026 regarding Lumee Oxygen?
How will Dr. Theodosios Bisdas use Lumee Oxygen in Greece for PFSA?
Does the announcement mention Dr. Bisdas's clinical or research credentials relevant to PFSA (PFSA)?
Will Profusa (PFSA) expand its vascular network as a result of this agreement?
Does the press release provide financial guidance or revenue impact from the Dr. Bisdas collaboration for PFSA (PFSA)?
